$77.07 -$0.36 (-0.5%)

04:00 PM EST on 11/21/19

BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)

CAPS Rating: 3 out of 5

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Current Price $77.07 Mkt Cap $13.8B
Open $77.28 P/E Ratio 0.00
Prev. Close $77.43 Div. (Yield) $0.00 (0.0%)
Daily Range $76.21 - $77.37 Volume 1,721,909
52-Wk Range $62.88 - $100.13 Avg. Daily Vol. 1,607,541

Caps

How do you think NASDAQ:BMRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

913 Outperform
55 Underperform
 

All-Star Players

161 Outperform
14 Underperform
 

Wall Street

18 Outperform
1 Underperform
 

Top NASDAQ:BMRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

d3ming (64.21)
Submitted January 31, 2014

zzporte

GundersonGroup (28.15)
Submitted November 05, 2012

The global target market for Morquio syndrome patients with ability to pay for treatment is around 2500 patients. ThinkEquity analyst Kimberly Lee estimates the market potential of GALNS at 575 million annually. This would be $230,000 annually per… More

NASDAQ:BMRN VS S&P 500 (SPY)

Fools bullish on NASDAQ:BMRN are also bullish on:

Fools bearish on NASDAQ:BMRN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about BMRN.

Recs

0
Member Avatar TMFEBCapital (85.15) Submitted: 6/7/2018 9:49:55 AM : Outperform Start Price: $92.15 NASDAQ:BMRN Score: -27.92

Palynziq could address more PKU patients than BMRN's Kuvan (its second best-seller) and that means 400 mn plus in annual revenue. Mgmt thinks that if it's widely adopted, it's peak sales could be $1 bn. Given BMRN's sales of 1.3 billion in 2017, that represents a significant potential increase that could finally get this company in the black. The big kicker here, though, is the hemophilia A R&D program, which could have data as soon as next year. A win there would revolutionize treatment and potentially, relegate prophylaxis factor VII replacement to the past.

Recs

0
Member Avatar TMFSaintCroix (98.94) Submitted: 1/14/2018 3:14:30 PM : Outperform Start Price: $84.41 NASDAQ:BMRN Score: -45.92

These guys have found a cure for hemophilia. 400,000 people with hemophilia in the world. And BioMarin and Spark are going to make this disease gone.

Wow. Kudos. Outperform.

Recs

0
Member Avatar OleSmoky (68.08) Submitted: 1/9/2017 10:14:43 PM : Outperform Start Price: $91.31 NASDAQ:BMRN Score: -52.62

Pricy, but I believe this has a bright future for those who are patient.

Leaderboard

Find the members with the highest scoring picks in BMRN.

Score Leader

Jmcq88

Jmcq88 (86.26) Score: +758.20

The Score Leader is the player with the highest score across all their picks in BMRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BreakerBeth 97.26 5/17/2006 Outperform 5Y $12.26 +528.63% +158.57% +370.06 1 Comment
RBBioContest06 62.78 6/1/2006 Outperform 1Y $13.05 +490.57% +160.84% +329.73 1 Comment
GlobalTraveler 75.79 3/5/2009 3/17/2010 Outperform 3Y $10.04 +667.63% +358.88% +308.75 0 Comment
kaywonder < 20 3/6/2009 3/8/2010 Outperform 5Y $10.11 +662.31% +362.02% +300.29 0 Comment
vacafun4 94.07 3/6/2009 Outperform 3Y $10.18 +657.07% +362.36% +294.71 0 Comment
makednoc < 20 3/9/2009 2/8/2011 Outperform 3Y $10.29 +648.98% +357.76% +291.22 0 Comment
MellieMel777 53.50 9/29/2006 Outperform 3Y $14.41 +434.84% +146.24% +288.59 1 Comment
DamYankee < 20 9/29/2006 Outperform 1Y $14.41 +434.84% +146.24% +288.59 0 Comment
rolloro 42.77 10/2/2006 Outperform 3Y $15.00 +413.80% +146.71% +267.09 1 Comment
taxisvs 64.57 10/2/2006 Outperform NS $15.00 +413.80% +146.71% +267.09 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for BMRN.